US OptionsDetailed Quotes
AMGN240830C345000
- 0.06
- -0.16-72.73%
15min DelayTrading Aug 26 14:53 ET
0.40High0.06Low
0.12Open0.22Pre Close53 Volume95 Open Interest345.00Strike Price611.00Turnover27.02%IV5.75%PremiumAug 30, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type0.0271Delta0.0068Gamma2719.08Leverage Ratio-0.0592Theta0.0010Rho73.73Eff Leverage0.0215Vega
Amgen Stock Discussion
Sign in to post a comment
Morning Movers
Gapping up
$Shopify (SHOP.US)$ stock soared 17% after the e-commerce platform surpassed quarterly revenue expectations, with its artificial intelligence-powered tools attracting more merchants.
$Disney (DIS.US)$ stock rose by 0.16% in volatile trading as its Entertainment unit, housing Disney+, Hulu, and ESPN+, turning a profit for the first time.
Gapping down
$Super Micro Computer (SMCI.US)$ stock fell 14.2% follo...
Gapping up
$Shopify (SHOP.US)$ stock soared 17% after the e-commerce platform surpassed quarterly revenue expectations, with its artificial intelligence-powered tools attracting more merchants.
$Disney (DIS.US)$ stock rose by 0.16% in volatile trading as its Entertainment unit, housing Disney+, Hulu, and ESPN+, turning a profit for the first time.
Gapping down
$Super Micro Computer (SMCI.US)$ stock fell 14.2% follo...
33
5
$Amgen (AMGN.US)$ is scheduled to announce Q2 earnings results on 06 August (Tuesday) after the market close.
Amgen (AMGN) reported adjusted EPS of $3.96 in Q1 on revenue of $7.45B that grew 22% Y/Y. The drugmaker had also tweaked its annual outlook at the time, guiding for adjusted EPS of $19 to $20.20 on revenue of $32.5B to $33.8B.
With the expectation of continued positive commentary on MariTide, the company’s injected GLP-1 weight-lo...
Amgen (AMGN) reported adjusted EPS of $3.96 in Q1 on revenue of $7.45B that grew 22% Y/Y. The drugmaker had also tweaked its annual outlook at the time, guiding for adjusted EPS of $19 to $20.20 on revenue of $32.5B to $33.8B.
With the expectation of continued positive commentary on MariTide, the company’s injected GLP-1 weight-lo...
+2
13
$Amgen (AMGN.US)$ trend seems okay...hmmm wonder how well it close tmr
$Amgen (AMGN.US)$ 🚨
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO
5
» 15+ upcoming FDA decisions to watch: 👀 👇
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Eli Lilly and Co (LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron (GERN.US)$ : Imetelstat
$Merck & Co (MRK.US)$ : V116
$Amgen (AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Merck & Co (MRK.US)$ : KEYTRUDA ...
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Eli Lilly and Co (LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron (GERN.US)$ : Imetelstat
$Merck & Co (MRK.US)$ : V116
$Amgen (AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Merck & Co (MRK.US)$ : KEYTRUDA ...
16
I hate these days. I know it's investing & I'm long with my bets, but I have better, more exciting days when I don't see a lot of red. Sucks. And, I was terminated from my job in April & having a hard time getting unemployment. I was a 1099 contractor on that job & the department of labor doesn't know how to process my claim. This is making me low on hard cash & I'm going to have to sell a position or 2, and I DO NOT WANT TO DO THAT, especially with $Esperion Therapeutics (ESPR.US)$. I read...
7
3
$Esperion Therapeutics (ESPR.US)$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
$Viking Therapeutics (VKTX.US)$ yes company very cheap considering how much total market valuations the other three companies have achieved from just GLP-1 market (Obesity) contribution alone
$Eli Lilly and Co (LLY.US)$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S (NVO.US)$ 50-100 Billion if not wrong
$Amgen (AMGN.US)$ 20+ Billion on no data yet
$Eli Lilly and Co (LLY.US)$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S (NVO.US)$ 50-100 Billion if not wrong
$Amgen (AMGN.US)$ 20+ Billion on no data yet
1
2
See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb (BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna (MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals (CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro...
$Bristol-Myers Squibb (BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna (MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals (CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro...
8
1
📣 2 PDUFAs left in May!
🗓️ Last week’s PDUFAs:
$Amgen (AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb (BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies (DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S (ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...
🗓️ Last week’s PDUFAs:
$Amgen (AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb (BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies (DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S (ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...
10
No comment yet
Michael Tan053 : Moomoo informations updated surprisingly good
Michael Tan053 : Moomoo giving away free stocks for investment what good about stock after Monday collapses
Michael Tan053 : Fed Chairman cutting interest rates?
Paul Anthony : how take the time for your wonderful comments
山芭佬 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")